Koers ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Aandelen
1541
CNE100006624
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
15,1 HKD | +1,07% | +5,74% | -49,50% |
Omzet 2023 | 386K 53,27K 417K 49,82K | Omzet 2024 * | 1,35 mln. 187K 1,46 mln. 175K | Marktkapitalisatie | 5,23 mld. 722 mln. 5,65 mld. 675 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 * | - | Nettowinst (verlies) 2024 * | - | EV/omzet 2023 | 25.574 x |
Nettoliquiditeiten 2023 | 297 mln. 40,93 mln. 320 mln. 38,28 mln. | Nettoliquiditeiten 2024 * | 127 mln. 17,54 mln. 137 mln. 16,4 mln. | EV/omzet 2024 * | 3.770 x |
K/w-verhouding 2023 * |
-
| K/w-verhouding 2024 * |
-
| Werknemers | 145 |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 30,46% |
1 dag | +1,07% | ||
1 week | +5,74% | ||
Lopende maand | -6,44% | ||
1 maand | -3,21% | ||
3 maanden | -39,36% | ||
6 maanden | -47,11% | ||
Lopend jaar | -49,50% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Wen Zhi Tian
CEO | Chief Executive Officer | - | 01-06-15 |
Qi Ying Lu
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-22 |
Song Li
CTO | Chief Tech/Sci/R&D Officer | - | 01-12-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chi Tat Yeung
BRD | Director/Board Member | 55 | - |
Zhi Hua Yu
BRD | Director/Board Member | 56 | - |
Wen Zhi Tian
CEO | Chief Executive Officer | - | 01-06-15 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 15,1 | +1,07% | 287 600 |
25-04-24 | 14,94 | +2,05% | 135 800 |
24-04-24 | 14,64 | +2,23% | 130 800 |
23-04-24 | 14,32 | -1,78% | 66 600 |
22-04-24 | 14,58 | +2,10% | 33 000 |
uitgestelde koers Hong Kong S.E., 26 april 2024 om 10:08 uur
Meer koersenChiffre d''affaires - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-49,50% | 722 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |